For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Whey Protein Isolate + KHCO3 | 1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3 whey protein isolate: one 15-25 gm (based on body weight) protein packet three times a day with each meal potassium bicarbonate (KHCO3): two 13.5 mmol capsules three times a day with each meal | 0 | None | 3 | 35 | 22 | 35 | View |
| Whey Protein Isolate + Microcrystalline Cellulose | 1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules whey protein isolate: one 15-25 gm (based on body weight) protein packet three times a day with each meal microcrystalline cellulose: identical placebo capsule | 0 | None | 2 | 36 | 14 | 36 | View |
| Maltodextrin Powder + KHCO3 | isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3 potassium bicarbonate (KHCO3): two 13.5 mmol capsules three times a day with each meal maltodextrin powder: isocaloric placebo powder | 0 | None | 3 | 35 | 18 | 35 | View |
| Maltodextrin Powder + Microcrystalline Cellulose | isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules microcrystalline cellulose: identical placebo capsule maltodextrin powder: isocaloric placebo powder | 1 | None | 3 | 35 | 14 | 35 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Cardiovascular event | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Fall with musculoskeletal complication | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Peptic ulcer | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pedal edema | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Myocardial infaction | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| coronary heart disease | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Ear infection | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Benign Positional Vertgo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Abdominal discomfort | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Respiratory infections | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| GERD | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Peptic ulcer | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Fall with injury | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Joint pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Leg cramps | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Basal cell cancer | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |
| Depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Prostate problems | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| cerebrovascular event | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Dental infection | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Food poisoning | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Hyperkalemia | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Lightheadedness | SYSTEMATIC_ASSESSMENT | General disorders | None | View |